MaxCyte, Inc. Launch of Offering and Application to List (4538G)
July 26 2021 - 6:14AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 4538G
MaxCyte, Inc.
26 July 2021
MaxCyte Announces Launch of Offering and Application to List on
the Nasdaq Global Market
This announcement contains inside information
GAITHERSBURG, MD, July 26, 2021 - MaxCyte, Inc., (LSE: MXCT,
MXCN), a leading provider of platform technologies for cell
engineering, today announced the commencement of an underwritten
offering of 12,000,000 shares of common stock (the "Offering") at
an expected offering price between $11.50 and $13.50 per share. All
shares to be sold in the Offering will be offered by MaxCyte. In
addition, MaxCyte intends to grant the underwriters a 30-day option
to purchase up to 1,800,000 additional shares of common stock.
MaxCyte has applied to have its common stock listed on the
Nasdaq Global Market ("Nasdaq") under the symbol "MXCT." Upon
completion of the Offering, MaxCyte's common stock will continue to
be admitted to trading on the AIM market of the London Stock
Exchange (the "AIM") under the symbols "MXCT" and "MXCN."
Application will be made for the shares of common stock to be
issued at the closing of the Offering to be admitted to trading on
AIM.
Cowen, Stifel and William Blair are acting as joint book-running
managers for the Offering and as representatives of the
underwriters for the Offering. BTIG and Stephens Inc. are also
acting as co-managers of the Offering.
The Offering will be made only by means of a prospectus. Copies
of the preliminary prospectus relating to and describing the terms
of the Offering may be obtained from the offices of Cowen and
Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717, Attn: Prospectus Department, by
telephone at (833) 297-2926 or by email at
PostSaleManualRequests@broadridge.com; Stifel, Nicolaus &
Company, Incorporated, Attention: Prospectus Department, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at +1 (415) 364-2720 or by email at
syndprospectus@stifel.com; or William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, by telephone at 1-800-621-0687 or by email at
prospectus@williamblair.com.
A registration statement relating to these securities has been
filed with the SEC, but has not yet become effective. These
securities may not be sold, nor may offers to buy these securities
be accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities law of any
such state or jurisdiction.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. MaxCyte's existing
customer base ranges from large biopharmaceutical companies -
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue - to hundreds of
biotechnology companies and academic centers focused on
translational research. MaxCyte has granted 13 strategic platform
licenses to commercial cell therapy developers covering more than
75 programs under clinical licenses that are part of the strategic
platform licenses. MaxCyte was founded in 1998 and is headquartered
in Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black / Duncan Monteith / Matthew O'Dowd +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700 +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com maxcyte@consilium-comms.com
Chris Welsh
US IR Adviser david@gilmartinir.com
Gilmartin Group
David Deuchler, CFA
Forward-Looking Statements
Certain statements made in this press release are
forward-looking statements including with respect to the Offering.
These forward-looking statements are not historical facts but
rather are based on the Company's current expectations, estimates,
and projections about its industry; its beliefs; and assumptions.
Words such as "anticipates," "expects," "intends," "plans,"
"believes," "seeks," "estimates" and similar expressions are
intended to identify forward-looking statements. These statements
are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which
are beyond the Company's control, are difficult to predict, and
could cause actual results to differ materially from those
expressed or forecasted in the forward-looking statements,
including if the Company's registration statement is not declared
effective by the SEC, if Nasdaq fails to approve the Company's
common stock listing application or if there are adverse market or
economic conditions. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this press release. The forward-looking
statements made in this press release relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBQLFLFDLFBBL
(END) Dow Jones Newswires
July 26, 2021 06:14 ET (10:14 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024